AK129 Combination Therapy for Advanced Solid Tumors

NCT06943820 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage IIIB/IV
Head and Neck Squamous Cell Carcinoma (HNSCC)
Colorectal Adenocarcinoma
Advanced Solid Tumors

Interventions

DRUG: AK129(dose 1)
DRUG: Pemetrexed
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: AK129(dose 2)
DRUG: Docetaxel
DRUG: Cis-platinum
DRUG: 5-FU (5-fluorouracil)
DRUG: Cetuximab
DRUG: Paclitaxel
DRUG: Docetaxel
DRUG: Chemotherapy
DRUG: AK129(RP2D)
DRUG: Penpulimab

Sponsor

Akeso